

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of October 2023**

**Commission File No. 001-39621**

---

**OPTHEA LIMITED**

**(Translation of registrant's name into English)**

---

**Level 4  
650 Chapel Street  
South Yarra, Victoria, 3141  
Australia**  
**(Address of registrant's principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes  No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

---

---

EXHIBIT INDEX

Exhibit	Description
99.1	<a href="#">Press Release: Opthea to Participate at the 2023 Euretina Congress</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**OPTHEA LIMITED**

(Registrant)

By: /s/ Megan Baldwin

Name: Megan Baldwin, Ph.D.

Title: Chief Executive Officer and Managing Director

Date: 10/2/2023

---



## ASX, Nasdaq and Media Release

October 2, 2023

### Opthea to Participate at the 2023 Euretina Congress

Melbourne, Australia; October 2, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4<sup>th</sup>, Dr. Megan Baldwin, the Company's Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization's 23<sup>rd</sup> Congress being held on October 5<sup>th</sup> – 8<sup>th</sup> in Amsterdam, The Netherlands.

The **Euretina Innovation Spotlight (EIS) event is intended to** foster direct collaboration and communication between industry, regulators, investors, researchers and physicians involved or interested in the retinal innovation space. This one day conference features panel discussions and talks by selected industry leaders, biomedical innovators, regulators and investors. Dr. Baldwin will be a speaker on the Innovation in Treatment Modalities panel taking place on October 4<sup>th</sup> at 2:00PM CEST.

Euretina was started in 2000 and was originally known as the European Retina, Macula and Vitreous Society. Today, the organization has grown to over 4,500 members and hosts annual Congress that attracts thousands of delegates from around the world. For information on the Euretina Congress or the EIS, please visit <https://euretinacongress.org>.

---



### **About Opthea Limited**

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea's lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

### **Inherent risks of Investment in Biotechnology Companies**

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

**Authorized for release to ASX by Megan Baldwin, CEO & Managing Director**

#### ***Company & Media Enquiries:***

##### ***U.S.A. & International:***

Megan Baldwin, CEO  
Opthea Limited  
Tel: +61 447 788 674

##### ***Australia:***

Rudi Michelson  
Monsoon Communications  
Tel: +61 (0) 3 9620 3333

##### ***Media:***

Hershel Berry  
Blueprint Life Science Group  
Tel: +1 415 505 3749  
hberry@bplifescience.com

#### ***Join our email database to receive program updates:***

Tel: +61 (0) 3 9826 0399  
Email: [info@opthea.com](mailto:info@opthea.com)  
Web: [www.opthea.com](http://www.opthea.com)

---

